Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Osteosarcoma treatment faces challenges with systemic drug delivery and side effects.
• Targeted drug delivery systems are crucial for improving therapeutic efficacy and reducing toxicity.

Purpose of the Study:

• To develop novel paclitaxel nanoparticles (Nps) coated with polydopamine (PDA) and grafted with alendronate (ALN) for targeted osteosarcoma therapy.
• To evaluate the physicochemical properties, in vitro cytotoxicity, in vivo biodistribution, and therapeutic efficacy of these targeted nanoparticles.

Main Methods:

• Fabrication of paclitaxel nanoparticles (PTX-PDA-ALN-Nps) using dopamine polymerization and alendronate grafting.
• Characterization of nanoparticle size, zeta potential, stability, and drug release kinetics.
• In vitro cytotoxicity assays using K7M2 osteosarcoma cells.
• In vivo biodistribution studies and antitumor efficacy evaluation in relevant models.

Main Results:

• The developed nanoparticles exhibited a mean particle size of 290.6 nm and a negative zeta potential (-13.4).
• PTX-PDA-ALN-Nps demonstrated sustained drug release and stability in various physiological conditions.
• In vitro studies showed enhanced cytotoxicity against osteosarcoma cells compared to non-targeted nanoparticles.
• In vivo studies indicated preferential accumulation in tumor tissues and superior antitumor effect with reduced side effects.

Conclusions:

• Paclitaxel nanoparticles functionalized with polydopamine and alendronate represent a promising targeted delivery strategy for osteosarcoma.
• This approach offers improved therapeutic outcomes and a potentially better safety profile for osteosarcoma treatment.